Skip to the main content.
Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Turn Our Insights Into Your Impact

From early feasibility to commercialization, progress depends on the right decisions at the right time. Get confident in your next step with blogs, case studies, and expert insights that cut through complexity and move development forward.

 

7 min read

Where Is There Still Room for Innovation in Cardiovascular Devices That the Market Will Fund?

Where Is There Still Room for Innovation in Cardiovascular Devices That the Market Will Fund?
Where Is There Still Room for Innovation in Cardiovascular Devices That the Market Will Fund?
12:50

By Nicolas Borenstein, DVM, PhD

Every Idea Needs to Survive Three Problems

In my experience, every new cardiovascular-device concept has to solve three problems in order to achieve commercial success: a clinical problem, a regulatory problem, and a financial problem.

The clinical or scientific question is whether it meaningfully improves durability, safety, invasiveness, or access to care. The regulatory question is whether it is acceptable to regulatory bodies. Can it be demonstrated, compared, and approved within a credible development path? The commercial or financial question is whether the benefit is valuable enough, and achievable soon enough, to justify the capital required. Does the return justify the investment and the wait?

Right now, the financial problem decides most of them. Capital was easy for a stretch after COVID, when money had gone unused for eighteen months. That ended. Return on investment is not what it used to be. An investor does not need certainty, but they do need a credible path to return capital within a fundable horizon, not 20 years.

The question is not only where there is room to improve. It is where will the market fund improvement.

I spend my working life watching innovation arrive in an operating room. Innovation is what gets me up in the morning. The market does not need another ten or fifteen transcatheter aortic valve platforms. That space is taken. The problems around the platform are not.

One Caution Before the Cardiovascular Innovation Opportunities: Start with the Problem, Not the Capability

This work is hard enough without the one mistake that dooms projects in any funding environment, so I will put it first.

Programs I see rarely fail because they are not clever enough. Concepts can be brilliant and still fail to achieve commercial success. They fail because they started with a capability instead of a problem. Someone arrives with a technique, sometimes a beautiful one, and asks what it might be good for. Or they pick a problem large enough for their ego, which is how people end up trying to reinvent the heart. I am not above either impulse. My own PhD was in cell therapy, where we promised more than we delivered when its hype was inescapable in the early 2000s.

Stay open to material science, to chemistry, to anything that might serve a patient. Start with the problem and reason toward the device. Everything below assumes you have.

Improve the Device, Not the Category

Most of the good work in this field addresses what people call the little things, which are not little when they decide whether a patient lives well. Less thrombus. Slower degeneration, less infection, less obstruction of the outflow tract. Some groups pursue that through the leaflets alone, building engineered rather than bioprosthetic ones. Others rethink how the stent and the leaflets relate: place the metal beside the leaflets instead of crimping one inside the other, and you stop damaging them during delivery, which protects durability over the life of the implant. It also opens the door to something smaller.

[Directly related reading: A New Chapter for the Heart Valve: Foldax's TRIA(TM) TAVR Promising Preclinical Results in npj Cardiovascular Health.]

One engineer I know well has spent his career near transcatheter valves. His current company does not build one. It builds something that sits on the stent and serves as a pacemaker, because the conduction system runs close to the left ventricular outflow tract, and a stent landing in a calcified annulus crushes what sits in its way. Some valves have carried atrioventricular block rates above 20 percent, and while some of those patients recover within a month, many keep a pacemaker for life. His solution rides on anyone's valve and could well solve an unmet need with potential to improve outcomes while reducing overall cost of care within a development timeline investors can support.

Drug - Device Convergence Remains a Strong Opportunity

The most underrated room in cardiovascular innovation sits between a drug and a device, and the clearest analog is one everybody already understands: the drug-eluting stent.

That lineage is worth remembering, because it shows how much value an addition can carry. A balloon in the eighties. A bare stent a few years later. Then, toward the end of the nineties, a stent that elutes a compound to suppress restenosis, which changed coronary intervention outright. Nobody reinvented the artery or the stent. They added something. The same logic moved into peripheral arteries, then onto balloons, and we recently completed a large drug-eluting balloon study here in Paris, so this is not history to us.

Now push the logic one step further. Valves fail because they degenerate and calcify. I recently read a very interesting paper on drugs that reduce the mineralization driving that process. A stented valve that elutes such a compound is a reasonable thought and a fundable one, and it asks nobody to reinvent the valve.

The opportunity is not that every drug-device pairing is ready for clinical use. It is that the drug-eluting-stent model provides a proven commercial and regulatory precedent for asking which local therapy can make an established implant perform better.

The pairing runs in the other direction too: a drug carried to its target by a device. We worked on a catheter designed to inject cells directly into myocardial infarcts, and the interesting part is what it opened rather than what it treated. Perfectly targeted injection inside the heart serves RNA, gene therapy, or whatever targeted compound comes next. Cells and gene therapy have been promising for forty years, with real ups and downs, and I do not expect anyone to build something new out of old cardiac muscle. I do expect meaningful gain, and I expect a device to be the route in. That is biotech meeting medtech, and it is still genuinely unsolved.

Miniaturization and Access

Most transcatheter valve delivery systems still sit at 16 to 18 French. Rethought designs reach 8 to 10. That gap is the opportunity I would back first. Smaller means less tissue trauma, fewer access complications, and more patients who qualify for treatment at all.

Size also decides the route, and the route decides what the patient goes through. A transfemoral approach means sedation rather than general anesthesia. For a ninety-year-old with several comorbidities, that is the difference between a treatable problem and an untreatable one. My grandmother could not benefit from that in the early 1990s. Today she could, and she might have had five or 10 more years.

[Related reading: The Strategic Science of Preclinical Model Determination, Selection and Development] 

Imaging Is Where AI Earns Its Place

Let me be blunt about the incentive first. Put AI or robotics into a pitch, and you have a story a venture capitalist will listen to. That is not the same as having a product, and both deserve a harder test than they usually get.

Imaging passes that test today. AI-assisted mapping and better preoperative planning can identify, before the case begins, whether this particular anatomy will obstruct the outflow tract after implantation. You have changed nothing about the design and everything about the outcome. Build imaging into the device itself, and you get true targeting rather than inference, with the implant arriving exactly where you intended it to go. Pair preoperative imaging with 3D printing and you can make the valve for this patient rather than for a population: this is the valve for you, not the valve for your neighbor.

Robotics Has to Beat a Hand, and Improve Workflow Economics

Robotics has to earn its place at one of three levels: protecting staff from exposure, improving procedural precision or force control, or simplifying the workflow enough to reduce personnel and procedure burden. The last two are the more compelling patient and purchaser arguments.

Delivering a coronary stent robotically, when a physician does it just as well, protects the physician from radiation and does nothing for the patient. That is robotics for the sake of robotics, and I find it uninteresting.

The real bar is higher and worth clearing. Robotics earns its place when it adds a degree of freedom a hand cannot produce, combines movements that are difficult to control manually, or gives better control of the forces involved, which means more safety for the patient.

There is a commercial version of the same test, and it is the one I would put in front of an investor. A procedure that needs a surgeon, an interventional cardiologist, and an imaging specialist today, and one operator tomorrow, saves a hospital real money. That argument sells a system to the people who actually buy it, and it is far more honest than the word robotics on a slide. The equipment is expensive right now. Fifty years out the scale will be different, and we do have to think about fifty years out.

The gains do not have to be dramatic to be real. One system I have seen uses an electrically powered handle: a single operator clicks to release with one hand and holds the wire with the other. Elsewhere the same step occupies two people, one on the wire and one on the handle. That is a small improvement, and small improvements of that kind are what a meaningful delivery system improvement looks like.

Technologies Likely to Struggle for Funding

A mechanical valve with mechanical durability and no anticoagulation is a genuine need. Three or four companies work on it, and it is beginning to work. It is also a very surgical proposition and very hard to finance.

A new total artificial heart or left ventricular assist device will take at least ten years and possibly twenty. The French total artificial heart program began in 1995. Thirty years on, roughly 100 patients have been implanted, and it still needs substantial capital. Neither project is scientifically foolish. Both are financially brutal inside the window an investor accepts.

Evolution Before Revolution

Every 20 years or so this field produces a revolution. This might not be one of those moments, and that is fine. Useful evolution is worth more than a revolution nobody will fund. Keep it simple. Solve a clinically unmet need and make sure it is one the market will pay to have solved.

About the author: Nicolas Borenstein, DVM, PhD, is Co-President of Preclinical Contract Research Services at Veranex. He has led cardiovascular preclinical research at the Paris facility for more than 25 years and is a widely published author and peer-reviewed journal contributor in surgical and transcatheter preclinical science.

Preclinical & Pathology Callout

Regulatory bodies require safety and performance evidence before human trials can begin, but poorly designed preclinical studies don't just create delays - they waste the lives of animals and the hopes of patients waiting for better options. Veranex Preclinical Services approaches this responsibility with the intensity it deserves.

We deliver GLP and non-GLP studies across 11 therapeutic areas, with particular depth in cardiovascular technologies including TAVR and structural heart, where we set the industry standard. Our teams don't just execute protocols; they understand that translational science isn't copy-and-paste. Models have limitations, regulators know this, and our job is to design studies that generate the specific evidence your submission needs while respecting both the animals in our care and the patients waiting for your innovation.

Upstream, we can work with product development teams to ensure device readiness. Our integrated pathology services deliver insights on model optimization that improves interpretation and analysis without handoff delays, and our Regulatory Affairs teams use these findings to shape pre-sub meetings, regulatory submissions and trial designs. Downstream, our Clinical Research teams design first-in-human and pivotal trials informed by preclinical findings, while Commercial Strategy & Market Access ensures the evidence we generate aligns with payer requirements and reimbursement realities from the earliest stages. With over 100 regulatory submissions returned with no questions asked from preclinical data, we deliver evidence that clears the path to human trials and builds toward revenue.

If you're evaluating preclinical partners especially for cardiovascular or structural heart devices, or if you're navigating the path from prototype to GLP studies, contact Veranex Preclinical Services to learn how our teams can accelerate your regulatory pathway.